Cardiac Biofabrication Using Living Tissue Constructs

Abstract

Cardiac biofabrication using living tissue constructs represents a transformative approach in cardiovascular regenerative medicine. Recent advancements in tissue engineering, 3D bioprinting, and stem cell technology have enabled the development of engineered cardiac tissues that aim to restore myocardial function following injury. This review critically evaluates the current state of cardiac biofabrication, encompassing its epidemiological importance, underlying pathophysiology, risk factors for disease, clinical presentation, diagnostic approaches, treatment and management modalities, recent advances in biofabrication technologies, and relevant guideline recommendations. The article aims to provide clinicians and researchers with a comprehensive understanding of the mechanisms, potential clinical applications, and future directions of living tissue constructs in cardiac repair and regeneration.

Introduction

Cardiovascular diseases, particularly ischemic heart disease and heart failure, remain leading causes of morbidity and mortality worldwide. Traditional therapies, including pharmacological agents and device-based interventions, have improved patient outcomes but do not address the loss of functional myocardium following infarction. Cardiac biofabrication, utilizing living tissue constructs, has emerged as an innovative solution to regenerate and repair damaged myocardial tissue. This multidisciplinary field integrates principles from cell biology, materials science, bioengineering, and clinical cardiology to fabricate functional cardiac tissues that may one day revolutionize the management of heart disease. Understanding the scientific basis, clinical implications, and translational challenges of cardiac biofabrication is essential for advancing this promising therapeutic paradigm.

Epidemiology / Disease Burden

Globally, cardiovascular diseases account for approximately 17.9 million deaths annually, representing 31% of all global deaths. Myocardial infarction and heart failure, the principal targets for cardiac biofabrication, affect millions of individuals and impose a substantial economic and social burden. Despite advances in acute coronary care and chronic heart failure management, the prevalence of these conditions continues to rise, particularly in aging populations and those with comorbidities such as diabetes and hypertension. The limited regenerative capacity of adult myocardium underscores the urgent need for innovative strategies capable of restoring cardiac structure and function.

Pathophysiology

Following myocardial infarction, the loss of viable cardiomyocytes triggers an inflammatory response, leading to scar formation and adverse ventricular remodeling. This process is characterized by extracellular matrix deposition, fibrosis, and progressive decline in contractile function. The inability of mature cardiomyocytes to proliferate restricts endogenous myocardial regeneration. Biofabrication aims to overcome these limitations by providing structural and functional support through engineered tissues composed of cardiomyocytes, supporting cells, and biomimetic scaffolds. These constructs are designed to integrate with host tissue, promote neovascularization, and restore synchronous contractility.

Risk Factors

Risk factors for conditions necessitating cardiac biofabrication mirror those for ischemic heart disease and heart failure. Major contributors include hypertension, hyperlipidemia, diabetes mellitus, smoking, obesity, sedentary lifestyle, and genetic predisposition. The cumulative effect of these risk factors leads to coronary artery disease, myocardial infarction, and subsequent heart failure. Recognizing and modifying these risks remain critical for primary prevention, while regenerative strategies such as biofabrication offer hope for those with established disease and irreversible myocardial loss.

Clinical Features

Patients with advanced cardiac injury present with symptoms ranging from exertional dyspnea and fatigue to chest pain, palpitations, and signs of heart failure such as peripheral edema and pulmonary congestion. Chronic heart failure may lead to exercise intolerance, cachexia, arrhythmias, and recurrent hospitalizations. The clinical sequelae of myocardial scarring and ventricular dysfunction highlight the need for novel interventions capable of restoring myocardial integrity and function, beyond symptomatic management.

Diagnosis

Diagnosis of cardiac damage suitable for biofabrication-based intervention requires multimodal assessment. Electrocardiography, cardiac biomarkers (e.g., troponin), echocardiography, and cardiac magnetic resonance imaging (MRI) are essential for detecting myocardial infarction, quantifying ventricular function, and delineating scar tissue. Advanced imaging allows for precise localization and characterization of myocardial injury, guiding patient selection for tissue engineering approaches. Endomyocardial biopsy may be considered in select cases to assess histopathological changes and inflammatory processes.

Treatment & Management

Current management of myocardial injury and heart failure includes optimal medical therapy (beta-blockers, ACE inhibitors, mineralocorticoid receptor antagonists), device therapy (implantable cardioverter-defibrillators, cardiac resynchronization), and surgical options (coronary artery bypass, ventricular assist devices, transplantation). However, these modalities do not regenerate lost myocardium. Cardiac biofabrication seeks to address this gap by implanting living tissue constructs engineered sheets, patches, or organoids composed of cardiomyocytes, endothelial cells, and extracellular matrix analogs. These constructs may be applied surgically or via minimally invasive techniques to augment ventricular function and promote tissue regeneration.

Recent Advances / Emerging Therapies

Recent years have witnessed significant progress in cardiac biofabrication. Advances in stem cell biology have enabled the derivation of induced pluripotent stem cell (iPSC)-derived cardiomyocytes with potential for autologous or allogeneic transplantation. Three-dimensional bioprinting technologies allow for precise spatial arrangement of cells and matrix materials, recapitulating the complex architecture of native myocardium. Vascularization remains a critical challenge; emerging strategies include pre-vascularization of constructs, incorporation of angiogenic factors, and use of decellularized scaffolds to enhance perfusion and integration. Preclinical studies demonstrate improved myocardial function, reduced scar size, and enhanced survival in animal models. Ongoing clinical trials are evaluating the safety and efficacy of engineered cardiac patches and cell-laden scaffolds in humans.

Guideline Recommendations

While cardiac biofabrication remains investigational, major cardiovascular societies emphasize the importance of rigorous clinical trials, standardized protocols, and long-term follow-up to establish safety and efficacy. Guidelines recommend that regenerative therapies should be pursued within controlled research settings with multidisciplinary oversight. Patient selection, informed consent, and risk-benefit assessment are paramount. Regulatory agencies advocate for robust manufacturing standards, quality control, and post-market surveillance as biofabricated products advance toward clinical application.

Conclusion

Cardiac biofabrication using living tissue constructs offers a promising avenue for myocardial regeneration and repair, addressing a critical unmet need in cardiovascular medicine. Continued advancements in cell engineering, biomaterials, and bioprinting are expected to enhance the feasibility, safety, and efficacy of these innovative therapies. As the field progresses from bench to bedside, close collaboration among scientists, clinicians, and regulatory bodies will be essential to realize the full potential of biofabricated cardiac tissues in improving patient outcomes and transforming the management of heart disease.